CoChat

T cell toxicity induced by tigecycline binding to the mitochondrial ribosome

Open access
Shao, Qiuya, Khawaja, Anas, Nguyen, Minh Duc, Singh, Vivek, Zhang, Jingdian, Liu, Yong, Nordin, Joel, Adori, Monika, Axel Innis, C., Castro Dopico, Xaquin, Rorbach, Joanna · 2025 · Nature Communications

Published version of a preprint

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Tetracyclines are essential bacterial protein synthesis inhibitors under continual development to combat antibiotic resistance yet suffer from unwanted side effects. Mitoribosomes - responsible for generating oxidative phosphorylation (OXPHOS) subunits - share structural similarities with bacterial machinery and may suffer from cross-reactivity. Since lymphocytes rely upon OXPHOS upregulation to establish immunity, we set out to assess the impact of ribosome-targeting antibiotics on human T cells. We find tigecycline, a third-generation tetracycline, to be the most cytotoxic compound tested. In vitro, 5–10 μM tigecycline inhibits mitochondrial but not cytosolic translation, mitochondrial complex I, III and IV expression, and curtails the activation and expansion of unique T cell subsets. By cryo-EM, we find tigecycline to occupy three sites on T cell mitoribosomes. In addition to the conserved A-site found in bacteria, tigecycline also attaches to the peptidyl transferase center of the large subunit. Furthermore, a third, distinct binding site on the large subunit, aligns with helices analogous to those in bacteria, albeit lacking methylation in humans. The data provide a mechanism to explain part of the anti-inflammatory effects of these drugs and inform antibiotic design.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-59388-9

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Tigecycline compromises human T cell activation and proliferation by inhibiting mitochondrial translation. A Representative dose-response curves of tetracycline antibiotic cytotoxicity towards PBMCs (left; n = 5) and Jurkat T cells (right; n = 3) measured 72 h after treatment; mean ± SEM is presented. Data are normalized to DMSO treatment without antibiotics. B Representative dose-response curves for additional bacterial protein synthesis inhibitors on PBMCs for 72 h. n = 6 biological replicates; mean ± SEM. Data are shown relative to DMSO treatment without antibiotics. C 35S metabolic labeling assay of mitochondrial (left) and cytosolic (right) translation in Jurkat T cells after 18 h treatment with Q/D, tigecycline, or doxycycline. One representative result from n = 3 is shown. D Western blot OXPHOS profiling in Jurkat T cells after treatment with Q/D, tigecycline, and doxycycline and PBMCs after treatment with tigecycline for 6 days. n = 2 biological replicates, one shown. E Seahorse Mito Stress Test of PBMCs cultured with or without tigecycline for 6 days after stimulation with anti-CD3/CD28 antibodies + IL-2 (10 ng/ml). OCR is reported as picomoles (pmol) of O2 per min and normalized according to protein amount/well. n = 4 biological replicates, mean ± SEM. Oligo, oligomycin; FCCP, carbonyl cyanide-p-tri-fluoromethoxyphenylhydrazone; Rot, rotenone; AA, antimycin A. F CD25 expression (MFI) on CD4+ and CD8+ T cells 18 h after anti-CD3/CD28 activation + IL-2 (10 ng/ml) in the presence or absence of tigecycline. n = 3 biological replicates, mean ± SEM. An RM one-way ANOVA with Tukey’s multiple comparisons test was used to analyze the data. G T cell proliferation assessed by flow cytometry. PBMC T cells were stimulated with anti-CD3/CD28 beads + IL-2 (10 ng/ml) in the presence or absence of tigecycline. Proliferation was assessed by CTV dilution in live cells after 6 days (n = 5 blood donor PBMC samples). PBMCs were labelled with CTV prior to stimulation. H Percentage of live T cells in division four or later after antibiotic treatment; data from (G), mean ± SEM. An RM one-way ANOVA with Tukey’s multiple comparisons test was applied to analyze the data. I Proliferation of FACS-isolated CD45RA+CD27+ naïve, CD45RA-CD27+ central memory, and CD45RA-CD27- effector memory CD4+ T cells from healthy blood donors after 6 days of stimulation with anti-CD3/CD28 beads and IL-2 (10 ng/ml). FACS-isolated cells were seeded in the presence or absence of tigecycline (from 2.5 to 10 μM) and proliferation assessed by CTV dilution in live cells (n = 3 blood donor PBMC samples). Representative dot plots from non-treated and treated samples are shown. The FACS gating strategy is shown in Supplementary Fig. 2G. J Percentage of live CD4+ T naïve cells and central memory cells in each division; data from (I); mean ± SEM. Tn: naïve T cells; Tcm: central memory T cells; Tem: effector memory T cells. Source data for all panels are provided as a Source Data file.
Fig. 1 Tigecycline compromises human T cell activation and proliferation by inhibiting mitochondrial translation. A Representative dose-response curves of tetracycline antibiotic cytotoxicity towards PBMCs (left; n = 5) and Jurkat T cells (right; n = 3) measured 72 h after treatment; mean ± SEM is presented. Data are normalized to DMSO treatment without antibiotics. B Representative dose-response curves for additional bacterial protein synthesis inhibitors on PBMCs for 72 h. n = 6 biological replicates; mean ± SEM. Data are shown relative to DMSO treatment without antibiotics. C 35S metabolic labeling assay of mitochondrial (left) and cytosolic (right) translation in Jurkat T cells after 18 h treatment with Q/D, tigecycline, or doxycycline. One representative result from n = 3 is shown. D Western blot OXPHOS profiling in Jurkat T cells after treatment with Q/D, tigecycline, and doxycycline and PBMCs after treatment with tigecycline for 6 days. n = 2 biological replicates, one shown. E Seahorse Mito Stress Test of PBMCs cultured with or without tigecycline for 6 days after stimulation with anti-CD3/CD28 antibodies + IL-2 (10 ng/ml). OCR is reported as picomoles (pmol) of O2 per min and normalized according to protein amount/well. n = 4 biological replicates, mean ± SEM. Oligo, oligomycin; FCCP, carbonyl cyanide-p-tri-fluoromethoxyphenylhydrazone; Rot, rotenone; AA, antimycin A. F CD25 expression (MFI) on CD4+ and CD8+ T cells 18 h after anti-CD3/CD28 activation + IL-2 (10 ng/ml) in the presence or absence of tigecycline. n = 3 biological replicates, mean ± SEM. An RM one-way ANOVA with Tukey’s multiple comparisons test was used to analyze the data. G T cell proliferation assessed by flow cytometry. PBMC T cells were stimulated with anti-CD3/CD28 beads + IL-2 (10 ng/ml) in the presence or absence of tigecycline. Proliferation was assessed by CTV dilution in live cells after 6 days (n = 5 blood donor PBMC samples). PBMCs were labelled with CTV prior to stimulation. H Percentage of live T cells in division four or later after antibiotic treatment; data from (G), mean ± SEM. An RM one-way ANOVA with Tukey’s multiple comparisons test was applied to analyze the data. I Proliferation of FACS-isolated CD45RA+CD27+ naïve, CD45RA-CD27+ central memory, and CD45RA-CD27- effector memory CD4+ T cells from healthy blood donors after 6 days of stimulation with anti-CD3/CD28 beads and IL-2 (10 ng/ml). FACS-isolated cells were seeded in the presence or absence of tigecycline (from 2.5 to 10 μM) and proliferation assessed by CTV dilution in live cells (n = 3 blood donor PBMC samples). Representative dot plots from non-treated and treated samples are shown. The FACS gating strategy is shown in Supplementary Fig. 2G. J Percentage of live CD4+ T naïve cells and central memory cells in each division; data from (I); mean ± SEM. Tn: naïve T cells; Tcm: central memory T cells; Tem: effector memory T cells. Source data for all panels are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Overview of the interactions of tigecycline with the human mitoribosome. A Chemical structure of tigecycline. B Overview of the three tigecycline (purple) binding sites in complex with the human mitoribosome comprising the mtSSU (yellow), mtLSU (blue), mRNA (red), and P-site tRNA (green). The mL45 (magenta) is depicted with its N-terminal extension occupying the exit tunnel. C mtSSU site: tigecycline overlaps with the A-tRNA binding site and is stabilized through multiple interactions. The residues from 12S rRNA which makes direct contact with tigecycline are shown. D mtLSU site-1: a novel tigecycline binding site located at helix 71 of the 16S rRNA, close to the acceptor stem of P-tRNA. E mtLSU site-2: tigecycline is positioned in the PTC where it stacks against the neighboring nucleotides and makes potential contact with mL45 N-terminus. Carved EM density is shown for tigecycline.
Fig. 2 Overview of the interactions of tigecycline with the human mitoribosome. A Chemical structure of tigecycline. B Overview of the three tigecycline (purple) binding sites in complex with the human mitoribosome comprising the mtSSU (yellow), mtLSU (blue), mRNA (red), and P-site tRNA (green). The mL45 (magenta) is depicted with its N-terminal extension occupying the exit tunnel. C mtSSU site: tigecycline overlaps with the A-tRNA binding site and is stabilized through multiple interactions. The residues from 12S rRNA which makes direct contact with tigecycline are shown. D mtLSU site-1: a novel tigecycline binding site located at helix 71 of the 16S rRNA, close to the acceptor stem of P-tRNA. E mtLSU site-2: tigecycline is positioned in the PTC where it stacks against the neighboring nucleotides and makes potential contact with mL45 N-terminus. Carved EM density is shown for tigecycline.CC BY · PubMed Central
Fig. 3 The conserved binding site of tigecycline on the mtSSU. A Tigecycline establishes canonical interactions with the 12S rRNA of the mtSSU accompanied by coordinated Mg2+ ions (lime) and waters (HOH) (red). Hydrogen bond interactions are indicated as dashed lines. B Structure of tigecycline (purple) (PDB: 5J9132) (C) and sarecycline (yellow) (PDB: 6XQD31), a tetracycline-derivative, in complex with the SSU of 70S ribosome from E.coli and T. thermophilis, respectively.
Fig. 3 The conserved binding site of tigecycline on the mtSSU. A Tigecycline establishes canonical interactions with the 12S rRNA of the mtSSU accompanied by coordinated Mg2+ ions (lime) and waters (HOH) (red). Hydrogen bond interactions are indicated as dashed lines. B Structure of tigecycline (purple) (PDB: 5J9132) (C) and sarecycline (yellow) (PDB: 6XQD31), a tetracycline-derivative, in complex with the SSU of 70S ribosome from E.coli and T. thermophilis, respectively.CC BY · PubMed Central
Fig. 4 Interaction of tigecycline with helix 71 of the mtLSU (mtLSU site-1) and its functional implications. A Tigecycline stabilizes in the binding pocket through multiple interactions either directly with the neighbouring nucleotides or indirectly through Mg2+ ion coordination as compared to the non-treated mitoribosomes (PDB:7QI435) (B). C The superposition shows the large displacement of H71 upon the binding of tigecycline. D The movement of nucleotide to create a cavity for the binding of tigecycline. The direction of conformational changes of nucleotides occurring upon binding of the drug are shown by arrows. Nucleotides, C2603 and U2628, undergo a large conformational change (bold arrows), while A2604, C2605 and C2606 move downward (smaller arrows) as compared to the non-bound mitoribosome (PDB: 7QI4) resulting in a binding site for the antibiotic. In E. coli (PDB: 5J9132), the flexible movement of this region is likely restricted by the presence of methylation of U1939. E The binding of tigecycline to the mtLSU site-1 might inhibit mitoribosome recycling. The RRF1-bound state (PDB: 7NSI37) was superimposed on the tigecycline-bound mitoribosome (this study). The insertion represents a close view at mtLSU site-1 to show the clash of the drug (purple stick and transparent grey sphere) with the RRF1 protein (green).
Fig. 4 Interaction of tigecycline with helix 71 of the mtLSU (mtLSU site-1) and its functional implications. A Tigecycline stabilizes in the binding pocket through multiple interactions either directly with the neighbouring nucleotides or indirectly through Mg2+ ion coordination as compared to the non-treated mitoribosomes (PDB:7QI435) (B). C The superposition shows the large displacement of H71 upon the binding of tigecycline. D The movement of nucleotide to create a cavity for the binding of tigecycline. The direction of conformational changes of nucleotides occurring upon binding of the drug are shown by arrows. Nucleotides, C2603 and U2628, undergo a large conformational change (bold arrows), while A2604, C2605 and C2606 move downward (smaller arrows) as compared to the non-bound mitoribosome (PDB: 7QI4) resulting in a binding site for the antibiotic. In E. coli (PDB: 5J9132), the flexible movement of this region is likely restricted by the presence of methylation of U1939. E The binding of tigecycline to the mtLSU site-1 might inhibit mitoribosome recycling. The RRF1-bound state (PDB: 7NSI37) was superimposed on the tigecycline-bound mitoribosome (this study). The insertion represents a close view at mtLSU site-1 to show the clash of the drug (purple stick and transparent grey sphere) with the RRF1 protein (green).CC BY · PubMed Central
Fig. 5 Interactions of tigecycline with the PTC (mtLSU site-2). Tigecycline occupies the PTC, with its 9-t-butylglycylamido substituent stretching adjacent to the P-tRNA (green), and the A ring interacting with the mL45 N-terminal extension (pink). Upon tigecycline binding, A2725 nucleobase shifts and stacks against ring D in both the P-tRNA only and the A- (blue), P-tRNA mitoribosomal classes, as compared to the untreated (tigecycline) mitoribosome (PDB:7QI435). G2992, U2993, and G3063 in the PTC rearranges upon binding of the A-tRNA (as also observed for the untreated mitoribosomes).
Fig. 5 Interactions of tigecycline with the PTC (mtLSU site-2). Tigecycline occupies the PTC, with its 9-t-butylglycylamido substituent stretching adjacent to the P-tRNA (green), and the A ring interacting with the mL45 N-terminal extension (pink). Upon tigecycline binding, A2725 nucleobase shifts and stacks against ring D in both the P-tRNA only and the A- (blue), P-tRNA mitoribosomal classes, as compared to the untreated (tigecycline) mitoribosome (PDB:7QI435). G2992, U2993, and G3063 in the PTC rearranges upon binding of the A-tRNA (as also observed for the untreated mitoribosomes).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 19

Metadata

Authors
Shao, Q., Khawaja, A., Nguyen, M. D., Singh, V., Zhang, J., Liu, Y., Nordin, J., Adori, M., Axel Innis, C., Castro Dopico, X., & Rorbach, J.
Affiliations
Karolinska Institutet (SE)
Corresponding author
Rorbach, Joanna
Venue
Nature Communications
Published
2025-05-01
Volume
16
Issue
1
Pages
4080-4080
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4410007480
Cited by
16
References
68
Citations by year
2026: 12 · 2025: 4
FWCI
4.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Knut och Alice Wallenbergs Stiftelse
  • Vetenskapsrådet
  • Karolinska Institutet
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
tigecycline, tetracycline, mitochondrial ribosome, T cell toxicity, oxidative phosphorylation, mitochondrial translation, peptidyl transferase center, antibiotic binding sites, T cell activation, antibiotic design, antibiotic resistance
MeSH terms
Mitochondrial Ribosomes, Tigecycline, Anti-Bacterial Agents, Binding Sites, Humans, Minocycline, Mitochondria, Oxidative Phosphorylation, T-Lymphocytes, Protein Biosynthesis, Cryoelectron Microscopy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T cell toxicity induced by tigecycline binding to the mitochondrial ribosome. https://app.cochat.ai/papers/10.1038/s41467-025-59388-9
The paper
Shao, Q., Khawaja, A., Nguyen, M. D., Singh, V., Zhang, J., Liu, Y., Nordin, J., Adori, M., Axel Innis, C., Castro Dopico, X., & Rorbach, J. (2025). T cell toxicity induced by tigecycline binding to the mitochondrial ribosome. Nature Communications. https://doi.org/10.1038/s41467-025-59388-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.